New York State Teachers Retirement System Sells 799 Shares of DaVita Inc. $DVA

New York State Teachers Retirement System lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 2.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,141 shares of the company’s stock after selling 799 shares during the quarter. New York State Teachers Retirement System owned about 0.05% of DaVita worth $5,576,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of DVA. Doma Perpetual Capital Management LLC raised its holdings in shares of DaVita by 172.3% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock valued at $44,110,000 after purchasing an additional 182,476 shares in the last quarter. Northern Trust Corp raised its holdings in shares of DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Nuveen LLC bought a new position in shares of DaVita during the 1st quarter valued at $20,218,000. Rovin Capital UT ADV bought a new position in shares of DaVita during the 1st quarter valued at $18,442,000. Finally, Amundi raised its holdings in shares of DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after purchasing an additional 71,304 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

NYSE DVA opened at $128.10 on Tuesday. The firm has a market capitalization of $9.16 billion, a price-to-earnings ratio of 12.60, a P/E/G ratio of 0.90 and a beta of 1.13. The company’s fifty day moving average is $132.46 and its two-hundred day moving average is $138.05. DaVita Inc. has a 52-week low of $122.93 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DVA has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Truist Financial set a $140.00 target price on shares of DaVita in a report on Tuesday, October 14th. Barclays dropped their target price on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating on the stock in a report on Thursday, October 9th. Bank of America dropped their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Finally, Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $153.25.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.